Interleukin-6 and hormonal biomarker profiles in Moroccan women with endometriosis

Endometriosis remains an underdiagnosed gynecological condition due to the lack of validated non-invasive biomark- ers. This study aimed to evaluate the diagnostic value of plasma interleukin-6 (IL-6), serum cancer antigen 125 (CA125), anti-Müllerian hormone (AMH), and other hormonal parameters in women with endometriosis.

A total of 224 Moroccan women (n=224) were recruited from a gynecology center in Morocco, including 112 patients with laparoscopically confirmed endometriosis and 112 asymptomatic controls. Plasma levels of IL-6 and serum levels of CA125, AMH, and gonadotropins were measured using enzyme-linked immunosorbent assay and electrochemilu- minescence immunoassay. The diagnostic performance was assessed using receiver operating characteristic curve anal- ysis.

Plasma IL-6 and serum CA125 levels were significantly elevated in the endometriosis group (P<0.001), whereas repro- ductive hormone levels were significantly lower (P<0.001). Among all biomarkers tested, IL-6 demonstrated the high- est diagnostic performance, with an area under the curve of 0.952, a sensitivity of 91.1%, and a specificity of 80.4%.

IL-6 may serve as a promising non-invasive biomarker for the detection of endometriosis, with superior diagnostic accuracy compared to currently used markers. Further multicenter validation is warranted to establish clinical cutoffs and confirm its utility in routine practice.

Endometriosis; Biomarkers; IL-6; CA-125 antigen; Gonadal hormones Original Article Obstet Gynecol Sci 2026;69(3):222-234 https://doi.org/10.5468/ogs.25347 eISSN 2287-8580 Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2026 Korean Society of Obstetrics and Gynecology Received: 2025.10.17. Revised: 2025.12.11. Accepted: 2026.03.10. Corresponding author: Chafika Nadifi, PhD Oncopathology Cancer Biology and Environment Laboratory, Mohammed VI Faculty of Medicine, Mohammed VI University of Health and Sciences (UM6SS), Casablanca 21000, Morocco E-mail: [email protected] https://orcid.org/0009-0005-7167-1025 www.ogscience.org 223 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers

Endometriosis is a chronic estrogen-dependent inflammatory disorder characterized by the presence of endometrial tissue outside the uterine cavity. It affects approximately 10% of women of reproductive age worldwide and is associated with severe symptoms, such as chronic pelvic pain, painful menstruation (dysmenorrhea), infertility, and irregular men - strual cycles. Beyond causing physical damage, endometriosis significantly reduces the quality of life and imposes a consid- erable psychological and economic burden on both patients and healthcare systems [1-3]. Despite its high prevalence, the diagnostic delay for endometriosis remains unacceptably long, averaging between 7 years and 10 years from symp - tom onset [4,5]. This delay is largely due to the reliance on laparoscopy as the gold standard for diagnosis; however, this procedure is invasive, costly, and not always accessible. There is a pressing need for non-invasive biomarkers that can en - able earlier detection and guide clinical management. Recent studies have focused on identifying circulating bio - markers involved in inflammation, angiogenesis, and ovarian func tion. Interleukin-6 (IL-6) is a central proinflammatory cyto kine that contributes to ectopic tissue proliferation, im - mune dysregulation, and pain sensitization in endometriosis [6]. A 2024 systematic review and meta-analysis by Doli ńska et al. [7] underscored the diagnostic promise of multi-cyto - kine panels including IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and vascular endothelial growth gactor, hence the im portance of further research in this area. In addition to inflammation, there is growing recognition of the link between chronic immune activation and impaired ovarian reserve. Anti-Müllerian hormone (AMH), a widely accepted marker of ovarian function, is expressed at lower levels in women with endometriosis. This hormone reduction is directly linked to cytokine-mediated effects, follicular injury, oxidative stress, and surgical intervention complications [8]. Cancer antigen 125 (CA125), a glycoprotein known primarily as a tumor marker, especially for ovarian cancers, has also been associated with endometriosis in moderate-to-severe cases. These markers may be useful, multifaceted diagnostic tools [9,10]. To date, most biomarker studies have focused on Euro - pean, Asian, or North American populations, with limited representation of North African women despite the potential influence of genetic, immunological, environmental, and healthcare access-related factors on disease presentation [11]. In this context, the present prospective study was conducted at a gynecology center in Morocco to evaluate the diagnostic value of IL-6, CA125, AMH, and other hormonal parameters in a cohort of North African women.

1. Study population This prospective case-control study was conducted between August 2024 and May 2025 at a fertility center in Casablan- ca, Morocco. In total, 224 women aged 19-52 years partic - ipated in this study, comprising 112 patients with patholog - ically confirmed endometriosis and 112 healthy controls. A 1:1 ratio was chosen to ensure balanced group comparisons, minimize sampling bias, and optimize the statistical power. Participants were recruited from gynecology clinics and re - ferrals for laparoscopic evaluation. This study was approved by the Institutional Ethics Committee (approval no. [CE/ UM6SS/25/24]), and written informed consent was obtained from all participants. The inclusion criteria were women diagnosed with endo - metriosis via laparoscopy with no prior ovarian surgery or endocrine disorders. It also included women of Moroccan origin from a single ethnic background. Moroccan women with suspected or confirmed malignancy, pregnancy, post - menopausal status, or refusal to participate were excluded. Endometriosis severity was classified according to the revised American Society for Reproductive Medicine classifi - cation system. Based on the laparoscopic findings, patients were categorized into four stages: stage I (minimal): 1-5 points; stage II (mild): 6-15 points; stage III (moderate): 16-40 points; and stage IV (severe): >40 points. This classification was used to assess disease progression. 2. Sample collection and processing Peripheral venous blood samples were collected under sterile conditions immediately before laparoscopy, between 07:30 AM and 09:30 AM, to minimize circadian variation in cytokine concentrations during the follicular phase (from day 3 to day 10 of the follicular phase of the menstrual cycle) and reduce hormonal variability, particularly for sensitive markers such as IL-6 and CA-125. Plasma was separated within 30 minutes of collection by centrifugation at 1,800 rpm for 15 minutes www.ogscience.org224 Vol. 69, No. 3, 2026 and stored at -20°C in ethylenediaminetetraacetic acid-coat- ed tubes for subsequent analysis. Serum samples were ob - tained from dry tubes using the same centrifugation proce - dure. 3. Biomarker measurement Quantitative detection of IL-6 levels was performed using sandwich enzyme-linked immunosorbent assay kits, Elecsys ® IL-6 (Roche Diagnostics, Penzberg, Germany), with a sensitiv- ity of 1.5 pg/mL and specificity of 84%. CA125 levels were measured using an Elecsys ® electroche- miluminescence immunoassay system, with a diagnostic thres hold of 35 IU/mL. Hormonal markers, including AMH, estra diol (E2), follicle-stimulating hormone (FSH), luteinizing hor mone (LH), and thyroid hormones (thyroid-stimulating hormone [TSH] thyroxine [T4]), were analyzed using a Roche Cobas 6000 analyzer, module e601 (Roche Diagnostics). All assays were conducted in triplicate to ensure precision, with intra- and inter-assay coefficients of variation maintained at <5% and <10%, respectively. 4. Statistical analysiss Data were analyzed using Microsoft Excel (Microsoft Cor - poration, Redmond, WA, USA), DATAtab (DATAtab, Graz, Austria), and GraphPad Prism version 10 (GraphPad Soft - ware, San Diego, CA, USA). The distribution of all variables was assessed using the Shapiro-Wilk normality test. Because the biomarkers showed non-normal distributions, the results were reported as median values with interquartile ranges (IQR). Comparisons between two groups were performed using the Mann-Whitney U -test, while comparisons across more than two groups were conducted using the Krus - kal-Wallis test, followed by Dunn’s post-hoc multiple compar- ison test when applicable. Correlations between biomarkers and clinical or hormonal parameters were assessed using Spearman’s rank correlation coefficient (ρ). Statistical signifi- cance was set at P<0.05. 5. Ethical considerations The study protocol adhered to the principles outlined in the Declaration of Helsinki and was approved by the institutional ethics committee (approval no. [CE/UM6SS/25/24]). Written informed consent was obtained from all participants prior to enrollment.

1. Clinical characteristics of participants In total, 112 Moroccan women with endometriosis and 112 Moroccan control participants were included in this study. The mean age was 35.48±5.64 years in the endometriosis group and 34.08±7.82 years in the control group; P=0.0499, indicating a statistically significant difference between the two groups. Body mass index was significantly higher in women with endometriosis (25.74±4.71 vs. 23.29±4.75; P<0.001). The mean duration of infertility was 4.92±3.04 years, while all women in the control group had preserved fer tility. Advanced stages of endometriosis (stage III-IV) were pre dominant (n=83), with a substantial proportion of patients presenting as deep infiltrating endometriosis (DIE) (Table 1). 2. Biomarkers analysis As summarized in Table 2, plasma concentrations of IL-6 (40.42±25.07 pg/mL vs. 2.82±1.23 pg/mL; 37.3 [20.68-54.38] vs. 2.7 [1.9-3.5]; P <0.001) and serum concentration of CA125 (44.93±33.41 U/mL vs. 16.54±7.03 U/mL; 36 [18.0-65.6] vs. 14.75 [11.58-19.85]; P <0.001) were significantly higher in women with endometriosis compared to control patients, reflecting a persistent inflammatory response and increased lesion activity characteristic of the disease. From an endo - crine perspective, patients showed a marked reduction in AMH levels (1.28±0.97 ng/mL vs. 2.44±1.58 ng/mL; 1.2 [0.53-2.5] vs. 2.3 [1.08-3.0]; P <0.001), suggesting impaired ovarian reserve. E2 concentrations were also significantly lower in the endometriotic group (70.99±47.99 pg/mL vs. 118.18±46.45 pg/mL; 57.5 [39.0-85.25] vs. 127.8 [83.98-150.38]; P<0.001), indicating ovarian hypo func tion that may result from an inflammatory microenvironment or follicular dam - age. LH levels were also significantly reduced in women with endometriosis compared to controls (5.57±3.53 IU/mL vs. 9.18±3.56 IU/mL; 4.95 [3.38-7.38] vs. 8.55 [6.5-10.9]; P<0.001), indicating a broader dysregulation of the hypo - thalamic-pituitary-ovarian (HPO) axis. In contrast, FSH levels were significantly elevated in patients compared to controls (8.36±4.66 IU/mL vs. 5.34±1.52 IU/mL; 8 [5.4-10.0] vs. 5.65 [4.3-6.7]; P<0.001), reflecting compensatory stimulation in response to declining ovarian function. Regarding thyroid function, TSH showed no significant difference between groups (2.60±1.95 vs. 2.56±1.25; 2 [1.02-3.3] vs. 2.6 [1.5-3.58]; P=0.2443). Although T4 was slightly reduced in patients www.ogscience.org 225 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers (11.74±5.82 vs. 12.94±2.07; 12 [9.0-14.88] vs. 12.9 [11.23- 14.48]; P=0.0125), the difference was of limited clinical magnitude. Overall, these findings underscore the combined inflammatory and endocrine disruptions associated with en - dometriosis (Table 2). Table 2. Analysis of biomarker profiles in Moroccan women with endometriosis compared to control groups Biomarker Endometriosis (n=112) Control (n=112) P-value (Mann-Whitney U-test) AMH (ng/mL) 1.28±0.97 b 1.2 (0.53-2.5) 2.44±1.58 2.3 (1.08-3.0) <0.001 IL-6 (pg/mL) 40.42±25.07 b 37.3 (20.68-54.38) 2.82±1.23 2.7 (1.9-3.5) <0.001 CA125 (U/mL) 44.93±33.41 b 36 (18.0-65.6) 16.54±7.03 14.75 (11.58-19.85) <0.001 LH (IU/mL) 5.57±3.53 b 4.95 (3.38-7.38) 9.18±3.56 8.55 (6.5-10.9) <0.001 FSH (IU/mL) 8.36±4.66 b 8 (5.4-10.0) 5.34±1.52 5.65 (4.3-6.7) <0.001 E2 (pg/mL) 70.99±47.99 b 57.5 (39.0-85.25) 118.18±46.45 127.8 (83.98-150.38) <0.001 TSH (mIU/mL) 2.60±1.95 2 (1.02-3.3) 2.56±1.25 2.6 (1.5-3.58) 0.2443 T4 (pg/mL) 11.74±5.82 a 12 (9.0-14.88) 12.94±2.07 12.9 (11.23-14.48) 0.0125 Values are presented as mean±standard deviation and median (interquartile range), where Q1 and Q3 represent the 25th and 75th percentiles, respectively. AMH, anti-Müllerian hormone; IL-6, interleukin-6; CA125, cancer antigen 125; LH, luteinizing hormone; IU, international unit; FSH, follicle- stimulating hormone; E2, estradiol; TSH, thyroid-stimulating hormone; T4, thyroxine (pg/mL). Indicates P-values: a significant P<0.05; b highly significant P<0.001. Table 1. Baseline characteristics of Moroccan women included in the study Characteristic Endometriosis (n=112) Control (n=112) P-value (Mann-Whitney U-test) Age (yr) 35.48±5.64 a 37 (31-40) 34.08±7.82 37 (28-40) 0.0499 BMI (kg/m 2 ) 25.74±4.71 b 25.7 (22.7-27.9) 23.29±4.75 23.85 (20.5-24.02) <0.001 Duration of infertility (yr) 4.92±3.04; (n=98) Fertile Malignancy Absence Absence ASRM classification Stages (I-II); (n=29) Stages (III-IV); (n=83) Surgical classification of endometriosis SUP P=21.42% DIE P=48.21% OMA P=12.52% DIE et OMA P=17.85% Values are presented as mean±standard deviation and median (interquartile range), where Q1 and Q3 represent the 25th and 75th percentiles, respectively. BMI, body mass index; ASRM, American Society for Reproductive Medicine; SUP , superficial peritoneal lesion; DIE, deep-infiltrating endometri- osis; OMA, ovarian endometrioma; DIE, deep infiltrating endometriosis. Indicates P-values: a P<0.05; b highly significant (P<0.001). www.ogscience.org226 Vol. 69, No. 3, 2026 1) Biomarker profiles across American Society for Reproductive Medicine stages of endometriosis Moroccan women with endometriosis demonstrated mark - edly elevated plasma IL-6 concentrations during the disease stages. Median IL-6 levels increased from 15.6 pg/mL in stage (I-II) to 38.2 pg/mL in stage (III-IV), compared with 2.7 pg/mL in controls (both P <0.0001 vs. controls). Although IL-6 con - centrations were higher in advanced disease, the difference between stage (I-II) and stage (III-IV) remained statistically sig- nificant (P=0.0159) (Fig. 1A). Similarly, serum CA125 levels were significantly increased from 27.7 U/mL in stage (I-II) to 46.0 U/mL in stage (III-IV); P=0.0259, while controls exhibited markedly lower levels (14.75 U/mL; P=0.0154 and P<0.0001, respectively) (Fig. 1B). In contrast, AMH levels, reflecting ovar- Fig. 1. Plasma concentrations of IL-6 and serum levels of CA125 and AMH according to endometriosis stages and the control group. Values are presented as scatter plots with medians and interquartile ranges. Group comparisons were performed using the Mann-Whitney U-test. (A) Plasma IL-6 (pg/mL) levels in women with endometriosis (stage I-II and stage III-IV) compared with healthy controls. (B) Serum CA125 (U/mL) levels in women with endometriosis (stage I-II and stage III-IV) compared with healthy controls. (C) Serum AMH (ng/mL) levels in women with endometriosis (stage I-II and stage III-IV) compared with healthy controls. IL-6, interleukin-6; CA125, cancer antigen 125; AMH, anti-Müllerian hormone; NS, not significant. Significance levels: *P<0.05; **P<0.01; ***P<0.0001. A 150 100 50 0 IL-6 (pg/mL) Stage (III-IV)Stage (I-II) Control *** **** B 200 150 100 50 0 CA125 (U/mL) Stage (III-IV)Stage (I-II) Control * * *** C 8 6 4 2 0 AMH (ng/mL) Stage (III-IV)Stage (I-II) Control ** NS *** Fig. 2. Distribution of IL-6, CA125, and AMH levels according to the different types of endometriosis (superficial [SUP], deep infiltrating endometriosis [DIE], ovarian endometriosis [OMA], DIE&OMA: combined lesions). Comparisons were performed using the Kruskal-Wallis test, followed by Dunn’s post hoc test for pairwise contrasts. (A) Plasma IL-6 (pg/mL) levels across different types of endometriosis (SUP , DIE, OMA, DIE&OMA). (B) Serum CA125 (U/mL) levels across different types of endometriosis (SUP , DIE, OMA, DIE&OMA). (C) Serum AMH (ng/ mL) levels across different types of endometriosis (SUP , DIE, OMA, DIE&OMA). IL-6, interleukin-6; NS, not significant; CA125, cancer antigen 125; AMH, anti-Müllerian hormone. Significance levels: *P<0.01; **P<0.001; ***P<0.0001. A 150 100 50 0 IL-6 (pg/mL) DIESUP OMA DIE&OMA *** ** Type of endometriosis NS B 150 100 50 0 CA125 (U/mL) DIESUP OMA DIE&OMA * * Type of endometriosis NS C 5 4 3 2 1 0 AMH (ng/mL) DIESUP OMA DIE&OMA *** *** Type of endometriosis ** www.ogscience.org 227 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers ian reserve, were reduced in stage (III-IV) (0.9 ng/mL) relative to stage (I-II) (1.9 ng/mL; P=0.0053) and control (2.3 ng/mL; P<0.0001). However, the difference between stage (I-II) and controls was not statistically significant (P =0.6109) (Fig. 1C). These findings show that IL-6 and CA125 levels increase in parallel with endometriosis severity, whereas the reduction in AMH levels appears to reflect an early impairment of ovarian function that is dependent on the disease stage. 2) Biomarker levels according to endometriosis types Plasma IL-6 concentrations were highest in patients with DIE associated with ovarian endometrioma (OMA) lesions (me - dian, 44 pg/mL), followed by patients with isolated DIE (43.07 pg/mL), OMA (34.07 pg/mL), and superficial perito - neal lesion (SUP; 15.08 pg/mL) (Fig. 2A). The Kruskal-Wallis test followed by Dunn’s post-hoc test showed that IL-6 was significantly higher in DIE than in SUP ( P<0.0001), and in DIE&OMA than in SUP (P =0.0001). Although the IL-6 con - centrations in the OMA did not differ significantly from those in the SUP (P=0.0695), the DIE phenotype showed the high- est IL-6 levels, reflecting the increased inflammatory burden characteristic of deep lesions. Similarly, serum CA125 concentrations increased propor - tionally with lesion complexity: DIE&OMA (51.15 U/mL), isolated DIE (40.1 U/mL), OMA (21.9 U/mL), and SUP (25.1 U/mL). CA125 was significantly elevated in DIE compared to SUP (P =0.0022), whereas OMA did not differ significantly from SUP (P>0.99). The DIE&OMA group showed the highest concentrations, clearly exceeding those in SUP (P =0.0086), highlighting the cumulative effect of deep and ovarian le - sions (Fig. 2B). In contrast, serum AMH levels were markedly reduced in the most severe phenotypes, particularly in women with combined DIE&OMA (0.78 ng/mL), followed by OMA (0.69 ng/mL), isolated DIE (0.90 ng/mL), and notably SUP (2.11 ng/mL). AMH levels were significantly lower in DIE than in SUP (P<0.0001), with an even more pronounced reduction in OMA ( P=0.0002). The DIE&OMA group exhibited the most significant decline, which differed significantly from that of the SUP (P<0.0001) (Fig. 2C). Overall, these results highlight Fig. 3. Scatter plots illustrating the correlation between plasma IL-6 levels and inflammatory, ovarian reserve, and hormonal biomarkers in patients with endometriosis. Associations were evaluated using Spearman’s rank correlation coefficient (ρ). Trend lines represent a non parametric regression. (A) Correlation between IL-6 (pg/mL) and CA125 (U/mL). (B) Correlation between IL-6 (pg/mL) and AMH (ng/mL). (C) Correlation between IL-6 (pg/mL) and FSH (IU/mL). (D) Correlation between IL-6 (pg/mL) and LH (IU/mL). (E) Correlation between IL-6 (pg/mL) and E2 (pg/mL). IL-6, interleukin-6; CA125, cancer antigen 125; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; IU, international unit; LH, luteinizing hormone; E2, estradiol. 150 100 50 0 0 50 100 150 200 CA125 (U/mL) IL-6 (pg/mL) ρ=0.3784 P<0.0001 A 150 100 50 0 0 1 2 3 4 5 AMH (ng/mL) IL-6 (pg/mL) ρ=-0.3389 P=0.0003 B 150 100 50 0 0 10 20 30 FSH (IU/mL) IL-6 (pg/mL) ρ=-0.07991 P=0.4023 C 150 100 50 0 0 5 10 15 20 25 LH (IU/mL) IL-6 (pg/mL) ρ=0.1031 P=0.2794 D 150 100 50 0 0 100 200 300 E2 (pg/mL) IL-6 (pg/mL) ρ=0.06391 P=0.5032 E www.ogscience.org228 Vol. 69, No. 3, 2026 an increasingly pronounced inflammatory burden and endo- crine impairment in the presence of deep, ovarian, or com - bined lesions, underlining the unfavorable biological profile associated with the most complex forms of endometriosis. 3) Correlation of IL-6 with hormonal and clinical biomarkers Spearman correlation ( ρ) revealed that IL-6 levels showed selective correlations with biomarkers of inflammation and ovarian reserve, but not with gonadotropins or E2. A moder- ate positive association was found between IL-6 and CA125 (ρ=0.3784; P<0.0001), suggesting that systemic inflamma - tion may mirror peritoneal immune activation in endometrio- sis (Fig. 3A). Conversely, IL-6 exhibited a negative correlation with AMH ( ρ=-0.3389; P=0.0003), supporting the hypothe- sis that inflammatory processes may contribute to a decline in ovarian reserve (Fig. 3B). No significant associations were observed between IL-6 and gonadotropins such as FSH ( ρ= -0.07991; P=0.4023) or LH ( ρ=0.2794; P=0.0131), nor with circulating E2 ( ρ=0.06391; P=0.5032) (Fig. 3C-E). Overall, these results highlight the specificity of IL-6 as an inflamma - tory marker, distinct from classical endocrine regulators, and underline its potential role at the interface between inflam - mation, ovarian dysfunction, and clinical expression of endo- metriosis. 4) Correlation of IL-6, CA125 and AMH with age The relationship between age and IL-6, CA125, and AMH levels was investigated in both the control and endometrio - sis groups. The IL-6 levels remained persistently elevated in patients across all age groups, with no significant correlation with age. Regression analysis confirmed the absence of as - sociation between IL-6 and age in the endometriosis group (ρ=0.02624), while controls exhibited a weak, non-significant positive correlation ( ρ=0.02214) (Fig. 4A). Similarly, CA125 levels were also consistently higher in patients compared to controls, with minimal age-related correlation in either group (ρ=0.1843 in endometriosis, ρ=-0.03115 in controls) (Fig. 4B). These findings suggest that IL-6 and CA125 are stable disease-specific biomarkers that are largely unaffected by chronological aging, reinforcing their diagnostic utility. In contrast, AMH levels exhibited a strong inverse correlation with age in controls (ρ=-0.9312), consistent with the expect- ed physiological decline in ovarian reserve. However, in endo- Fig. 4. Correlation of age with IL-6, CA125, and AMH levels in the endo metriosis and control groups; Spearman’s ρ values indicate the strength and direction of the association. (A) Correlation bet- ween age and IL-6 (pg/mL) in endometriosis and control groups. (B) Correlation between age and CA125 (U/mL) in endometriosis and control groups. (C) Correlation between age and AMH (ng/mL) in endometriosis and control groups. IL-6, interleukin-6; CA125, can- cer antigen 125; AMH, anti-Müllerian hormone. IL-6 of control IL-6 of endometriosis ρ=0.02214 (control) ρ=0.02624 (endometriosis) 150 100 50 0 20 40 60 Age (years) IL-6 (pg/mL) A CA125 of control CA125 of endometriosis ρ=-0.03115 (control) ρ=0.1843 (endometriosis) 150 100 50 0 20 30 40 50 60 Age (years) CA125 (U/mL) B AMH of control AMH of endometriosis ρ=-0.9312 (control) ρ=-0.3424 (endometriosis) 8 6 4 2 0 20 30 40 50 60 Age (years) AMH (ng/mL) C www.ogscience.org 229 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers metriosis patients, this relationship was substantially weaker (ρ=-0.3424), indicating considerable variability in AMH levels independent of age (Fig. 4C). This suggests that additional pathological factors, such as lesion type and severity of ovarian involvement, may influence ovarian reserve in this population. 5) Evaluation of the biomarker sensitivity and specificity by receiver operating characteristic (ROC) analysis ROC analysis demonstrated excellent diagnostic performance for IL-6, with an area under the curve (AUC) of 0.952 and sensitivity and specificity approaching 90% at the optimal cutoff value of 7.0 pg/mL, reflecting its strong association with inflammatory processes in Moroccan women with endo- metriosis (Fig. 5A). CA125 also showed excellent diagnostic accuracy (AUC=0.79) (Fig. 5B). Hormonal markers, including E2 and LH, demonstrated good discriminatory performance with AUCs of 0.78 and 0.798, respectively, supporting the involvement of ovarian hypofunction and HPO axis disrup - tion in the disease (Fig. 5E, F). AMH and FSH showed fair di- agnostic values, with AUCs of 0.721 and 0.752, respectively (Fig. 5C, D). These values reflect a reduction in the ovarian reserve and compensatory endocrine mechanisms, which have already been highlighted in previous analyses.

Diagnosing endometriosis remains a major challenge in gy - Fig. 5. ROC curve analysis of biomarkers in endometriosis. Data are presented as the area under the ROC curve (AUC) with 95% con fi- dence intervals. (A) ROC curve of IL-6 (pg/mL) for endometriosis diagnosis. (B) ROC curve of CA125 (U/mL) for endometriosis diagnosis. (C) ROC curve of AMH (ng/mL) for endometriosis diagnosis. (D) ROC curve of FSH (mIU/mL) for endometriosis diagnosis. (E) ROC curve of LH (mIU/mL) for endometriosis diagnosis. (F) ROC curve of E2 (pg/mL) for endometriosis diagnosis. ROC, receiver operating characteristic; IL-6, interleukin-6; AUC, area under the curve; CA125, cancer antigen 125; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol. 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of IL-6 (AUC=0.952)A 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of CA125 (AUC=0.79)B 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of AMH (AUC=0.721)C 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of FSH (AUC=0.752)D 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of LH (AUC=0.798)E 100 80 60 40 20 0 0 20 40 60 80 100 100%-specificity (%) Sensitivity (%) ROC of E2 (AUC=0.78)F www.ogscience.org230 Vol. 69, No. 3, 2026 necology despite the use of laparoscopy as the most validat- ed diagnostic approach. Although accurate, this technique is invasive, costly, and limited in detecting certain forms such as retroperitoneal lesions or DIE [12]. These limitations have driven researchers toward non-invasive approaches, notably the identification of reliable blood biomarkers, which could improve early diagnosis, patient stratification, and follow-up. Proinflammatory cytokines, lesion activity markers, hormones of ovarian function, and other plasma and serum factors are involved in immunity and angiogenesis [13,14]. This study is the first conducted on a North African (Mo - roccan) cohort to simultaneously evaluate a panel combining IL-6, CA125, AMH, and an extended set of reproductive and thyroid hormones (including FSH, LH, E2, T4, and TSH). The

of this study was to determine their diagnostic rele- vance and association with the disease stage and phenotype. Among these biomarkers, IL-6 showed the highest diagnostic accuracy, indicating its potential as a clinical tool for endome- triosis diagnosis. As a pleiotropic cytokine, IL-6 is produced in response to tissue injury by immune and endometrial cells and plays a central role in inflammation, angiogenesis, and modulation of the endometrial microenvironment [15]. Several studies have reported elevated IL-6 levels in plasma, serum, peritoneal fluid, and follicular fluid of women with endometriosis [16-18]. This increase reflects the chronic in - flammatory state of the disease. In our cohort of 112 patients, IL-6 concentrations were markedly higher than those in the controls (37.3 vs. 2.7 pg/mL; P<0.001), reflecting a pronounced systemic inflammatory state. Levels increased in parallel with disease severity, reach- ing 38.2 pg/mL in stage (III-IV) and peaking in patients with combined DIE&OMA (44 pg/mL), followed by isolated DIE (43.07 pg/mL), OMA (34.07 pg/mL), and SUP (15.08 pg/mL). These findings are consistent with those of several studies reporting elevated IL-6 concentrations in women with en - dometriosis compared with those in healthy controls. Des - dicioglu et al. [19] observed significantly higher serum IL-6 levels in patients with endometriosis (1.31±12.10 pg/mL) compared to controls (4.31±1.82 pg/mL; P<0.05). Similarly, Kashanian et al. [10] also demonstrated significantly elevated IL-6 levels in women with endometriosis (30.4±6.43 pg/mL) relative to controls (13.9±3.17 pg/mL), which closely approx- imates the values observed in our cohort. Conversely, several studies did not detect significant differences in IL-6 levels between patients with endometriosis and healthy controls. For example, Somigliana et al. [20] reported comparable IL-6 levels in affected and control participants (0.6 pg/mL [unde - tectable-1.4] vs. 1.0 pg/mL [0.4-1.9]; P =0.09), possibly due to their relatively small sample size, which included only 45 endometriosis cases. Regarding disease stage, our results showing a progressive increase in IL-6 concentrations with advancing endometriosis severity are in line with Li et al. [15], who found that serum IL-6 levels increased from 16.96±5.95 pg/mL in stage I-II to 22.77±11.02 pg/mL in stage III-IV, compared to 17.15±7.29 pg/mL in controls [17]. However, Martínez et al. [21] found that while serum IL-6 was elevated in women with min - imal-mild endometriosis (29.4±9.0 pg/mL), levels were paradoxically lower in advanced stages (17.6±10.3 pg/mL) compared with controls (15.7±9.3 pg/mL; P =0.002). The progressive increase in IL-6 with disease severity observed in our study supports its potential use as a marker of disease progression [21]. IL-6 levels were also independent of age and did not cor - relate with gonadotropin or E2 levels, suggesting its speci - ficity as an inflammatory marker rather than an endocrine surrogate. Its robust AUC (0.952), high sensitivity (91.1%), and high specificity (80.4%) further emphasize its diagnostic potential in clinical practice. These results align with those of Jiang et al. [22], who reported an AUC of 0.905 for IL-6, with 90.0% sensitivity and 93.7% specificity. However, Somi- gliana et al. [20] suggested that the ROC analysis of serum IL-6 levels was inadequate, and they observed low perfor - mance in detecting endometriosis. CA125, a historical biomarker of lesion activity, was also significantly elevated in patients (44.93 vs. 16.54 U/mL). Its progressive increase according to disease stage and lesion type, particularly in the DIE and DIE&OMA phenotypes, is consistent with its role in assessing lesion burden. These find- ings align with those of Jing et al. [23] and Kokot et al. [9], confirming the relevance of this marker in advanced forms, although its performance remains limited in early stages. We also observed a positive correlation between IL-6 and CA125 (ρ=0.3784; P<0.0001), consistent with Velasco et al. [24], who described a potential synergy between inflammation (IL-6) and lesion activity (CA125) in severe cases. Recent data have confirmed that panels combining IL-6, CA125, and angio - genic or neuroinflammatory markers significantly improve diagnostic accuracy [25,26]. Regarding AMH, our results reveal a significant reduction www.ogscience.org 231 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers in its concentration among women with endometriosis (1.28±0.97 ng/mL vs. 2.44±1.58 ng/mL; P <0.001), with a more pronounced decline in deep-infiltrating and cystic forms. These findings corroborate those of Garavaglia et al. [11] and Kasapoglu et al. [27], who demonstrated diminished ovarian reserves in severely diseased forms. The negative cor- relation between IL-6 and AMH ( ρ=-0.3389; P=0.0003) sug- gests a possible role of inflammation in follicular impairment, a hypothesis further supported by a recent study showing that IL-6 modulates follicular viability through the JAK/STAT3 and NF κB pathways [28]. ROC analyses demonstrated superior diagnostic perfor - mance of IL-6 (AUC=0.952), whereas CA125 (0.79), AMH (0.721), LH (0.798), and E2 (0.78) showed intermediate per- formance. These results, which outperform those reported by Mihalyi et al. [29] (AUC=0.75 for IL-6) and are consistent with the performance observed by Rokhgireh et al. [30] (AUC=0.90), reinforce the value of a multi-marker approach, particularly relevant in resource-limited settings. In parallel with Burghaus et al. [14], integrating IL 6 into artificial intelli- gence algorithms could enhance diagnostic performance. The hormonal pattern identified in our cohort-significant - ly elevated FSH (8.36±4.66 IU/mL), markedly reduced LH (5.57±3.53 IU/mL), and lower E2 levels (70.99±47.99 pg/mL) measured in the early-mid follicular phase (from day 3 to day 10 of the menstrual cycle)-is clinically and biologically plausi- ble and aligns with current evidence on inflammation-driven ovarian dysfunction in endometriosis. Recent multi-omics and mechanistic studies demonstrate that chronic exposure to IL-6, TNF- α, and oxidative stress can disrupt granulosa cell steroidogenesis, accelerate primordial follicle depletion, induce cortical fibrosis, and alter autophagy/ubiquitination pathways in ovarian endometriosis, as demonstrated by Nahdi et al. [31] and Ou et al. [32]. These alterations reduce E2 synthesis from developing follicles, weaken negative feedback to the hypothalamic-pituitary axis, and explain the compensatory rise in FSH observed in our patients. Impaired E2-mediated gonadotropin-releasing hormone pulsatility may attenuate LH secretion, consistent with the reduced LH levels found in our cohort. Evidence from animal models and ovarian tissue studies, such as those by Ge et al. [33] and Kanellopoulos et al. [34], further confirms that endometriosis can impair folliculogenesis, reduce AMH, and disrupt gonad- otropin responsiveness even without prior surgery, with the most pronounced effects occurring in endometrioma and DIE phenotypes. Importantly, not all previous studies have reported these hormonal changes. Somigliana et al. [20] and Mihalyi et al. [29] found no significant differences in gonadotropin or E2 levels between women with endometriosis and controls, highlighting the heterogeneity that is likely related to differ - ences in disease stage, phenotype distribution, or inadequate cycle-phase control. Large contemporary cohorts, including Ramezani Tehrani et al. [35] and Chung et al. [36], further emphasize that ovarian reserve decline is not universal, with preserved AMH in younger women and in those without sizeable or bilateral endometriomas, and underscore the confounding impact of prior cystectomy on ovarian reserve assessments. Therefore, the endocrine signature detected in our population likely reflects a high-risk inflammatory pheno- type with cortical ovarian involvement, rather than a uniform hormonal pattern across all patients with endometriosis. These findings suggest that our study is a valuable contrib - utor to clarifying the hormonal dynamics of endometriosis and emphasizes the clinical relevance of identifying distinct high-risk endocrine phenotypes. By integrating robust mech- anistic and clinical evidence, our results provide a strong foundation for future phenotype-specific and longitudinal research aimed at validating this hormonal signature as an early indicator of ovarian vulnerability and as a useful tool for individualized fertility management. Collectively, these findings suggest that endometriosis is characterized by a distinct biological signature encompassing systemic inflammation (IL-6), lesion activity (CA125), reduced ovarian reserve (AMH), and altered gonadotropin dynamics (FSH, LH, and E2). This integrated biomarker profile may be a powerful tool for non-invasive diagnosis, disease stratifica- tion, and monitoring. A distinctive feature of our cohort was that the levels of several biomarkers, particularly IL-6 and CA125, were higher than those reported in other populations. This difference may reflect genetic predisposition, lifestyle factors, environmental exposures such as pollution or endocrine disruptors, and eth- nicity-specific immune-inflammatory responses, all of which could amplify systemic inflammation in this population. Altogether, these results underscore the diagnostic poten - tial of a multi-marker panel comprising IL-6, CA125, AMH, and reproductive hormones, particularly in moderate-to-se - vere disease forms. The marked elevation of IL-6 in advanced stages, its high discriminatory power (AUC=0.952), and www.ogscience.org232 Vol. 69, No. 3, 2026 its inverse association with the ovarian reserve highlight its clinical relevance. CA125 similarly contributed to phenotypic differentiation despite its known limitations in early-stage disease. Although highly encouraging, these results warrant validation in larger, ethnically diverse cohorts to ensure ro - bustness and generalizability. Integrating these biomarkers into predictive models, po - tentially supported by artificial intelligence, may transform endometriosis management by enabling earlier detection, improved risk stratification, and personalized therapeutic strategies. Conflict of interest The authors declare that there are no conflicts of interest. Ethical approval The study was approved by the Ethics Committee of Mo - hammed VI University of Health Sciences (Approval No. [CE/ UM6SS/25/24]). Patient consent Written informed consent has been obtained from the pa - tients for the publication of this paper. Funding information This research received no external funding.

1. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P . Endometriosis. Nat Rev Dis Primers 2018; 4:9. 2. Ruszała M, Dłuski DF, Winkler I, Kotarski J, Rechberger T, Gogacz M. The state of health and the quality of life in women suffering from endometriosis. J Clin Med 2022; 11:2059. 3. Baradwan S, Gari A, Sabban H, Alshahrani MS, Kha - dawardi K, Bukhari IA, et al. The effect of antioxidant supple mentation on dysmenorrhea and endometriosis- associated painful symptoms: a systematic review and meta-analysis of randomized clinical trials. Obstet Gynecol Sci 2024;67:186-98. 4. Requadt E, Nahlik AJ, Jacobsen A, Ross WT. Patient ex - periences of endometriosis diagnosis: a mixed methods approach. BJOG 2024;131:941-51. 5. Lee HJ, Yoon SH, Lee JH, Chung YJ, Park SY, Kim SW, et al. Clinical evaluation and management of endometriosis: 2024 guideline for Korean patients from the Korean So - ciety of Endometriosis. Obstet Gynecol Sci 2025;68:43- 58. 6. Jørgensen H, Hill AS, Beste MT, Kumar MP , Chiswick E, Fedorcsak P , et al. Peritoneal fluid cytokines related to en- dometriosis in patients evaluated for infertility. Fertil Steril 2017;107:1191-9.e2. 7. Dolińska W, Draper H, Othman L, Thompson C, Girvan S, Cunningham K, et al. Accuracy and utility of blood and urine biomarkers for the noninvasive diagnosis of endo - metriosis: a systematic literature review and meta-analy - sis. F&S Rev 2023;4:116-30. 8. Romanski PA, Brady PC, Farland LV, Thomas AM, Horn - stein MD. The effect of endometriosis on the antimülle - rian hormone level in the infertile population. J Assist Reprod Genet 2019;36:1179-84. 9. Kokot I, Piwowar A, J ędryka M, Sołkiewicz K, Kratz EM. Diagnostic significance of selected serum inflammatory markers in women with advanced endometriosis. Int J Mol Sci 2021;22:2295. 10. Kashanian M, Sariri E, Vahdat M, Ahmari M, Moradi Y, Sheikhansari N. A comparison between serum levels of in- terleukin-6 and CA125 in patients with endometriosis and normal women. Med J Islam Repub Iran 2015;29:280. 11. Garavaglia E, Sala C, Taccagni G, Traglia M, Barbieri C, Ferrari S, et al. Fertility preservation in endometriosis pa - tients: anti-Müllerian hormone is a reliable marker of the ovarian follicle density. Front Surg 2017;4:40. 12. Chapron C, Marcellin L, Borghese B, Santulli P . Rethink- ing mechanisms, diagnosis and management of endo - metriosis. Nat Rev Endocrinol 2019;15:666-82. 13. Vodolazkaia A, El-Aalamat Y, Popovic D, Mihalyi A, Bossuyt X, Kyama CM, et al. Evaluation of a panel of 28 bio markers for the non-invasive diagnosis of endometri - www.ogscience.org 233 Chafika Nadifi, et al. Endometriosis: IL-6 & hormonal markers osis. Hum Reprod 2012;27:2698-711. 14. Burghaus S, Drazic P , Wölfler M, Mechsner S, Zeppernick M, Meinhold‐Heerlein I, et al. Multicenter evaluation of blood-based biomarkers for the detection of endometri - osis and adenomyosis: a prospective non-interventional study. Int J Gynaecol Obstet 2024;164:305-14. 15. Li T, Li RHW, Ng EHY, Yeung WSB, Chiu PCN, Chan RWS. Interleukin 6 at menstruation promotes the proliferation and self-renewal of endometrial mesenchymal stromal/ stem cells through the WNT/β-catenin signaling pathway. Front Immunol 2024;15:1378863. 16. Malutan AM, Drugan T, Costin N, Ciortea R, Bucuri C, Rada MP , et al. Clinical immunology pro-inflammatory cytokines for evaluation of inflammatory status in endo - metriosis. Cent Eur J Immunol 2015;40:96-102. 17. Li S, Fu X, Wu T, Yang L, Hu C, Wu R. Role of interleu - kin-6 and its receptor in endometriosis. Med Sci Monit 2017;23:3801-7. 18. Wójtowicz M, Zdun D, Owczarek AJ, Skrzypulec-Plinta V, Olszanecka-Glinianowicz M. Evaluation of proinflamma - tory cytokines concentrations in plasma, peritoneal, and endometrioma fluids in women operated on for ovarian endometriosis-A pilot study. Int J Mol Sci 2025;26:5117. 19. Desdicioglu MDR, Yildirim MM, Avcioglu MG, Özlem MEETM, Şengul MD, Yavuz MAF. Serum soluble uroki - nase-type plasminogen activator receptor (suPAR) and inter leukin-6 levels in endometriosis. WJPMR 2017;3:97- 101. 20. Somigliana E, Viganò P , Tirelli AS, Felicetta I, Torresani E, Vignali M, et al. Use of the concomitant serum dos - age of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of re pro ductive age women undergoing laparoscopic sur - gery for benign gynaecological conditions. Hum Reprod 2004;19:1871-6. 21. Martínez S, Garrido N, Coperias JL, Pardo F, Desco J, García-Velasco JA, et al. Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis. Hum Reprod 2007;22:836-42. 22. Jiang J, Jiang Z, Xue M. Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for en- dometriosis. Gynecol Endocrinol 2019;35:571-5. 23. Jing X, Li C, Sun J, Peng J, Dou Y, Xu X, et al. Systemic inflammatory response markers associated with infertility and endometrioma or uterine leiomyoma in endometri - osis. Ther Clin Risk Manag 2020;16:403-12. 24. Velasco I, Acién P , Campos A, Acién MI, Ruiz-Maciá E. Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aro - matase expression. J Reprod Immunol 2010;84:199-205. 25. Perricos A, Husslein H, Kuessel L, Gstoettner M, Wein - haeusel A, Eiwegger T, et al. Does the use of the "Pro - seek® Multiplex Inflammation I Panel" demonstrate a dif ference in local and systemic immune responses in endo metriosis patients with or without deep-infiltrating le sions? Int J Mol Sci 2023;24:5022. 26. Herranz-Blanco B, Daoud E, Viganò P , García-Velasco JA, Colli E. Development and validation of an endometriosis diagnostic method based on serum biomarkers and clin- ical variables. Biomolecules 2023;13:1052. 27. Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril 2018;110:122-7. 28. Hu Y, Chen H, Jin L, Chi X, Zhao J, Cao Q. Hypomethyl - ation of IL6ST promotes development of endometriosis by activating JAK2/STAT3 signaling pathway. PLoS One 2025;20:e0317569. 29. Mihalyi A, Gevaert O, Kyama CM, Simsa P , Pochet N, De Smet F, et al. Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Hum Reprod 2010;25:654-64. 30. Rokhgireh S, Mehdizadeh Kashi A, Chaichian S, Delban - di AA, Allahqoli L, Ahmadi-Pishkuhi M, et al. The diag - nostic accuracy of combined enolase/Cr, CA125, and CA19-9 in the detection of endometriosis. Biomed Res Int 2020;2020:5208279. 31. Nahdi S, Arafah M, Harrath AH. Integrated bioinformat - ics and experimental analysis revealed crosstalk between IL-6, autophagy, ubiquitination, and key miRNAs in fe - male infertility: insights from ovarian endometriosis and polycystic ovary syndrome. Cells 2025;14:1693. 32. Ou Y, Wang H, Zhou C, Chen Y, Lyu J, Feng M, et al. Endometriosis-associated infertility: multi-omics insights into pathogenesis and precision therapeutics. Front En - docrinol (Lausanne) 2025;16:1613334. 33. Ge L, Yang Y, Xiao T, Gao Y, Chang W, Du F, et al. Ovarian endometriosis accelerates premature ovarian failure and contributes to osteoporosis and cognitive decline in ag - ing mice. Int J Mol Sci 2025;26:3313. www.ogscience.org234 Vol. 69, No. 3, 2026 34. Kanellopoulos D, Karagianni D, Pergialiotis V, Nikiteas N, Lazaris AC, Iliopoulos D. The effect of endometriosis on fertility in an animal model. J Med Life 2022;15:1170-5. 35. Ramezani Tehrani F, Mousavi M, Noori Ardebili S, Saei Ghare Naz M, Azizi F, Behboudi-Gandevani S. Associa - tion between anti-mullerian hormone levels and age in women with endometriosis: insights from a population- based study. BMJ Open 2025;15:e102774. 36. Chung YS, Choi E, Baek JK, Kim H, Yun BH. Effects of endometriosis on anti-Müllerian hormone. J Clin Med 2025;14:4495.